Cargando…

Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2‐inhibitors versus other glucose‐lowering agents in real‐world clinical practice: Results from the CVD‐REAL study

The multinational, observational CVD‐REAL study recently showed that initiation of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2i) was associated with significantly lower rates of death and heart failure vs other glucose‐lowering drugs (oGLDs). This sub‐analysis of the CVD‐REAL study sought to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosiborod, Mikhail, Birkeland, Kåre I., Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Holl, Reinhard W., Norhammar, Anna, Jørgensen, Marit E., Wittbrodt, Eric T., Thuresson, Marcus, Bodegård, Johan, Hammar, Niklas, Fenici, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2018
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055705/ https://www.ncbi.nlm.nih.gov/pubmed/29569378 http://dx.doi.org/10.1111/dom.13299

Ejemplares similares

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
por: Kosiborod, Mikhail, et al.
Publicado: (2017)

Sodium–glucose cotransporter 2 inhibitors compared with other glucose‐lowering drugs in Japan: Subanalyses of the CVD‐REAL 2 Study
por: Kohsaka, Shun, et al.
Publicado: (2020)

Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
por: Lam, Carolyn S. P., et al.
Publicado: (2021)

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2017)

Cardiovascular and mortality benefits of sodium–glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia
por: Real, Jordi, et al.
Publicado: (2021)

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study
por: Birkeland, Kåre I., et al.
Publicado: (2019)

Renal outcomes and all‐cause death associated with sodium‐glucose co‐transporter‐2 inhibitors versus other glucose‐lowering drugs (CVD‐REAL 3 Korea)
por: Koh, Eun Sil, et al.
Publicado: (2020)

Cardiovascular and Renal Disease Burden in Type 1 Compared With Type 2 Diabetes: A Two-Country Nationwide Observational Study
por: Kristófi, Robin, et al.
Publicado: (2021)

Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
por: Pintat, Stéphane, et al.
Publicado: (2019)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
por: Hasvold, L P, et al.
Publicado: (2014)

Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink
por: Wilding, John, et al.
Publicado: (2018)

Different patterns of second‐line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
por: Persson, Frederik, et al.
Publicado: (2018)

Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014
por: Caspard, Herve, et al.
Publicado: (2017)

Glycaemic control in patients with type 2 diabetes initiating second‐line therapy: Results from the global DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2019)

Impact of micro‐ and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort study
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
por: Nyström, Thomas, et al.
Publicado: (2017)

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
por: Kosiborod, Mikhail, et al.
Publicado: (2018)

Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
por: Khunti, Kamlesh, et al.
Publicado: (2020)

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second‐line therapy: Results from the global DISCOVER study programme
por: Nicolucci, Antonio, et al.
Publicado: (2019)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
por: Hasvold, Pål, et al.
Publicado: (2015)

IDF2022-0622 Mortality and cardiorenal disease in type 1 and type 2 diabetes after COVID-19 and influenza hospitalization in Sweden
por: Kristófl, R., et al.
Publicado: (2023)

History of heart failure and chronic kidney disease and risk of all-cause death after COVID-19 during the first three waves of the pandemic in comparison with influenza outbreaks in Sweden: a registry-based, retrospective, case–control study
por: Ritsinger, Viveca, et al.
Publicado: (2023)

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
por: Khunti, Kamlesh, et al.
Publicado: (2017)

Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

Patients with type 1 and type 2 diabetes hospitalized with COVID-19 in comparison with influenza: mortality and cardiorenal complications assessed by nationwide Swedish registry data
por: Kristófi, Robin, et al.
Publicado: (2022)

Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry(®)
por: Arnold, Suzanne V., et al.
Publicado: (2017)

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study
por: Patel, Krishna K., et al.
Publicado: (2020)

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study
por: Birkeland, Kåre I., et al.
Publicado: (2020)

The multimorbidity epidemic: challenges for real-world research
por: Adan, Muna, et al.
Publicado: (2020)

SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
por: Kyriakos, Georgios, et al.
Publicado: (2020)

Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
por: Norhammar, Anna, et al.
Publicado: (2022)

Long COVID — metabolic risk factors and novel therapeutic management
por: Khunti, Kamlesh, et al.
Publicado: (2021)

Introduction: Real-World Evidence in Type 2 Diabetes
por: Hassanein, Mohamed, et al.
Publicado: (2020)

SUN-149 Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education
por: Gunawan, Felona, et al.
Publicado: (2019)

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician
por: Blonde, Lawrence, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ggas9n4hv6d3mkcv34da6n2ec